Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II/III clinical study on TOTUM•63: proven efficacy on the main risk factor of developing type 2 diabetes.
Valbiotis, a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the large success of the REVERSE-IT Phase II/III clinical study on TOTUM•63.
Conducted in 636 prediabetic and untreated type 2 diabetic patients (early stage), this international, multicentric, randomized and placebo-controlled study confirms the efficacy of TOTUM•63 in reducing fasting blood glucose at 2 and 3 intakes per day.
The results of the REVERSE-IT study on TOTUM•63 represent a major breakthrough in the fight against diabetes and its complications for people with prediabetes and untreated type 2 diabetes (early stage), by providing unequivocal clinical evidence that TOTUM•63 is a promising solution for millions of people worldwide, helping to prevent the progression to type 2 diabetes.
These positive results trigger a lump sum payment of CHF 4 million from Nestlé Health Science as part of the global strategic partnership. They also validate Valbiotis’ scientific approach, based on the use of innovative and patented combinations of plant-based active ingredients for the prevention of metabolic and cardiovascular diseases.